Hum. Reprod. Advance Access published online on November 16, 2006
Human Reproduction, doi:10.1093/humrep/del441
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
* To whom correspondence should be addressed. BACKGROUND: Controlled ovarian hyperstimulation with intrauterine insemination (IUI) is a widely accepted treatment for unexplained and male subfertility. No consensus exists about the drug of first choice to be used as hyper-stimulation. This randomized multicentre trial using a parallel design compares the efficacy of clomiphene citrate (CC) with that of recombinant FSH (rFSH). METHODS: Couples with primary unexplained or male subfertility were randomized to receive CC or rFSH for ovarian hyperstimulation. The treatment was continued for up to four cycles unless pregnancy occurred. Cycles with more than three follicles were cancelled. Cumulative pregnancy rates and live birth rates were primary outcomes. Cancellation during treatment and multiple birth rates are secondary outcomes. Results were analysed following the intention-to-treat principle. RESULTS: Seventy couples with male subfertility and 68 couples with unexplained subfertility were included. Seventy-one women received CC, and 67 received rFSH. Twenty-seven pregnancies were observed in the CC group (38%) and 23 in the rFSH group (34.3%) relative risk (RR) 1.11 [95% confidence interval (95% CI) 0.71-1.73]. The live birth rate was 28.2% (20/71) and 26.9% (18/67) for CC and rFSH, respectively, RR 1.05 (95% CI 0.61-1.80). Overall, the live birth rates per cycle were 10% for CC-stimulated and 8.7% for rFSH stimulated cycles. The total multiple pregnancy rate was 6.0%. Thirty-five cycles (8.6%) were cancelled because of four or more follicles (CC, n = 17; rFSH, n = 18). CONCLUSIONS: In couples with primary unexplained or male subfertility participating in an IUI program, ovarian hyperstimulation can be achieved by CC or rFSH. No significant difference in live birth rates between CC and rFSH was observed. Being less expensive, CC seems the more cost-effective drug and therefore, can be offered as drug of first choice.
Received August 19, 2006
Revised October 6, 2006
Accepted October 12, 2006
Article
A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility
T. Dankert 1 *, J.A.M. Kremer 1, B.J. Cohlen 2, C.J.C.M. Hamilton 3, P.C.M. Pasker-de Jong 4, H. Straatman 4, and P.A. van Dop 5
2 Department of Obstetrics and Gynecology, Isala Clinics, Zwolle, Nijmegen, The Netherlands
3 Department of Obstetrics and Gynecology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, Nijmegen, The Netherlands
4 Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
5 Department of Obstetrics and Gynecology, Catharina Hospital Eindhoven, Nijmegen, The Netherlands
T. Dankert, E-mail: t.dankert{at}obgyn.umcn.nl
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The ESHRE Capri Workshop Group Intrauterine insemination Hum. Reprod. Update, May 1, 2009; 15(3): 265 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pennings and W. Ombelet Coming soon to your clinic: patient-friendly ART Hum. Reprod., August 1, 2007; 22(8): 2075 - 2079. [Abstract] [Full Text] [PDF]
|
|